Results 221 to 230 of about 4,460,555 (293)

AZD6738 (Ceralasertib) Enhances Trifluridine's Antitumor Effect in 5‐FU–Resistant Colorectal Cancer Cells

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Resistance to 5‐fluorouracil (5‐FU) remains a major obstacle in colorectal cancer (CRC) treatment. Trifluridine (FTD), the active component of TAS‐102, exerts cytotoxicity through DNA incorporation and reportedly remains active in 5‐FU‐resistant tumors, though with limited clinical efficacy.
Shuhei Uehara   +11 more
wiley   +1 more source

Endogenous Bornavirus‐Like Nucleoprotein 1 Regulates Cellular Processes and DNA Double‐Strand Breaks in U‐87 MG Glioblastoma Cells

open access: yesCancer Reports, Volume 9, Issue 9, September 2026.
ABSTRACT Background Glioblastoma (GBM) is a common brain cancer with a poor prognosis and a high recurrence rate. DNA damage repair plays a crucial role in GBM carcinogenesis and treatment resistance. Human endogenous bornavirus‐like nucleoprotein 1 (EBLN1) regulates cellular processes and genetic stability. However, the biological role of EBLN1 in GBM
Jing Liang   +6 more
wiley   +1 more source

Lactoferrin and Nanotechnology: New Insights Into Glioblastoma Therapy

open access: yesCNS Neuroscience &Therapeutics, Volume 32, Issue 9, September 2026.
Current glioblastoma multiforme (GBM) management primarily relies on surgery, chemotherapy, and radiotherapy; however, therapeutic efficacy remains limited due to tumor invasiveness and restricted drug penetration across the blood–brain barrier. Lactoferrin (LF), an iron‐binding glycoprotein with receptor‐mediated transport capability, has emerged as a
Atena Abed, Javad Amini Mahabadi
wiley   +1 more source

MicroRNA Profiling of Oxaliplatin-Resistant HCT116 Colorectal Cancer Cells [PDF]

open access: yesOncomedicine, 2017
Bustamin Kosmo   +9 more
openaire   +1 more source

Cancer cell‐selective ectopic expression of CD20 as an antigen enables rituximab repurposing for solid tumour immunotherapy

open access: yesClinical and Translational Medicine, Volume 16, Issue 9, September 2026.
A recombinant AAV delivered tumour gene therapy. NF‐κB drives tumour‐selective antigen (e.g., CD20) expression. Ectopic CD20 enables rituximab repurposing to solid tumours. ADCC, ADCP, and CDC contribute to the antitumour activity. Abstract Background Despite the clinical success of cancer immunotherapies, their efficacy is often compromised by antigen‐
Ziyan Kong   +6 more
wiley   +1 more source

Home - About - Disclaimer - Privacy